Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bivalent COVID-19 mRNA vaccine (Zhongnan Hospital of Wuhan University)
- Development stage
- Unknown
- Lead developer
- Zhongnan Hospital of Wuhan University
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The Bivalent COVID-19 mRNA Vaccine is an intramuscularly administered booster vaccine designed to provide broad immunological protection against SARS-CoV-2. It utilizes a bivalent mRNA-based formulation that targets the spike proteins of both the ancestral (wild-type) strain and the Omicron BA.5 variant. By delivering genetic instructions to host cells, the vaccine induces the expression of these spike proteins, thereby stimulating the production of neutralizing antibodies and eliciting a memory B cell response. In clinical trials sponsored by Zhongnan Hospital, this bivalent mRNA booster was evaluated for its immunogenicity and safety in adults, demonstrating higher neutralizing antibody titers against Omicron subvariants compared to aerosolized adenovirus-vectored vaccines, albeit with a higher incidence of transient adverse reactions.
- Other names
- mRNA-based bivalent COVID-19 vaccinebivalent mRNA COVID-19 booster
02
Targets
BVDV E2 (Bovine viral diarrhea virus glycoprotein E2)Pattern-recognition receptors sensing exogenous mRNA (Toll-like receptor 7, Toll-like receptor 8, Toll-like receptor 3, Retinoic acid-inducible gene I, and Melanoma differentiation-associated protein 5)ACE2 (Angiotensin-converting enzyme 2)
Beyond the preview
Go deeper on bivalent COVID-19 mRNA vaccine (Zhongnan Hospital of Wuhan University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bivalent COVID-19 mRNA vaccine (Zhongnan Hospital of Wuhan University).